All In Biotech

Drug Trial Radar · NCT06624644

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Aug 6, 2025

Primary completion

Feb 2029

Study completion Feb 2031

Sponsor

Lead sponsor
Linnaeus Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will compare LNS8801 taken alone or LNS8801 taken together with another drug called pembrolizumab to other therapies as decided by the treating doctor. 135 patients will be randomly (like flipping a coin) placed in 3 treatment groups. In the first group (LNS8801 only) - Patients will take 125mg tablet of LNS8801 by mouth once per day every day for up to 2 years. In the second group (LNS8801 + pembrolizumab) - Patients will take 125mg tablet of LNS8801 by mouth once per day plus 200 mg of pembrolizumab by IV infusion once every 3 weeks for up to 2 years. In the third group, called Physician's Choice (PC), patients will receive chemotherapy (dacarbazine or temozolomide) or immunotherapy (pembrolizumab, nivolumab/relatlimab or nivolumab/ipilimumab) as determined by their treating physician. How often the patient visits the clinic visits will depend on the treatment group. Besides returning to the clinic for treatment, the patient will undergo periodic safety assessments and other required study procedures such as imaging assessments.

Conditions

  • Melanoma (Skin Cancer)
  • Melanoma Stage IIIB-IV
  • Cutaneous Melanoma
  • Unresectable Melanoma

Interventions

  • LNS8801Biological

    G protein-coupled estrogen receptor (GPER) agonist

  • PembrolizumabBiological

    Recombinant monoclonal antibody (anti-PD1)

  • Chemotherapy (dacarbazine or temozolomide)Drug

    chemotherapy (dacarbazine, temozolomide)

  • Immunotherapy (Pembrolizumab)Biological

    pembrolizumab

  • Immunotherapy (nivolumab and relatlimab)Biological

    nivolumab and relatlimab

  • Immunotherapy (ipilimumab and nivolumab)Biological

    ipilimumab and nivolumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare progression-free survival (PFS) of LNS8801 + pembrolizumab vs PC arms as assessed by RECIST v1.1.Time frame: up to 2 years.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • USC Newport Beach

    Newport Beach, California · Recruiting

  • UCSF

    San Francisco, California · Recruiting

  • Stanford

    Stanford, California · Recruiting

  • University of Colorado Anschutz

    Aurora, Colorado · Recruiting

  • University of Colorado

    Denver, Colorado · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Dana Farber

    Boston, Massachusetts · Recruiting

  • University of New Mexico

    Albuquerque, New Mexico · Recruiting

  • UPenn

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.